

Accepted Manuscript

Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids

Feng Gao, Hua Yang, Tianyu Lu, Zijian Chen, Long Ma, Zhi Xu, Paul Schaffer, Guangming Lu



PII: S0223-5234(18)30821-3

DOI: [10.1016/j.ejmech.2018.09.049](https://doi.org/10.1016/j.ejmech.2018.09.049)

Reference: EJMECH 10760

To appear in: *European Journal of Medicinal Chemistry*

Received Date: 10 January 2018

Revised Date: 11 September 2018

Accepted Date: 16 September 2018

Please cite this article as: F. Gao, H. Yang, T. Lu, Z. Chen, L. Ma, Z. Xu, P. Schaffer, G. Lu, Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids, *European Journal of Medicinal Chemistry* (2018), doi: <https://doi.org/10.1016/j.ejmech.2018.09.049>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids

Feng Gao¹, Hua Yang², Tianyu Lu³, Zijian Chen¹, Long Ma¹, Zhi Xu³, Paul Schaffer², Guangming Lu^{1*}

¹Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, P. R. China;

²Life Sciences, TRIUMF, Vancouver, Canada;

³Department of Neurosurgery, NanJing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, P. R. China



A series of novel benzofuran-isatin hybrids were designed, synthesized and evaluated for their *in vitro* anti-mycobacterial activities as well as cytotoxicity. Preliminary results indicated that all hybrids with acceptable cytotoxicity in VERO cells exhibited considerable anti-mycobacterial activities against MTB H₃₇Rv and MDR-TB strains. It is worthy to note that hybrid **8f** with no cytotoxicity towards VERO cells, was found to be the most active compound against MTB H₃₇Rv and MDR-TB. Comparing to the first-line anti-TB agents (rifampicin and isoniazid), hybrid **8f** has shown over two magnitude more active against MDR-TB. However, both the metabolic stability and *in vivo* pharmacokinetic profiles of **8f** were inferior to inhibitor **TAM16**. Further modification based on hybrid **8f** is needed to improve metabolic stability and pharmacokinetic profiles.

Download English Version:

<https://daneshyari.com/en/article/11027090>

Download Persian Version:

<https://daneshyari.com/article/11027090>

[Daneshyari.com](https://daneshyari.com)